Xinbang Pharmaceutical (002390.SZ): Net profit of 58.824,800 yuan in the first quarter increased 11.11% year-on-year
Gelonghui, April 28 | Xinbang Pharmaceutical (002390.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,582 billion yuan, down 1.41% year on year; net profit attributable to shareholders of listed companies was 588.24,800 yuan, up 11.11% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 5881.19 million yuan, up 14.70% year on year; basic earnings per share were 0.03 yuan.
Xinbang Pharmaceutical (002390.SZ): Net profit increased by 28.02% in 2023 to 287 million yuan, plans to distribute 10.0.6 yuan
Gelonghui, April 15 | Xinbang Pharmaceutical (002390.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 6.461 billion yuan, up 1.75% year on year; net profit attributable to shareholders of listed companies was 287 million yuan, up 28.02% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 268 million yuan, up 19.43% year on year; basic income per share was 0.15 yuan; it plans to distribute a cash dividend of 0.60 yuan (tax included) to all shareholders for every 10 shares.
Xinbang Pharmaceutical (002390.SZ) Pediatric Heat-clearing Ning Granules have the therapeutic function of clearing heat and detoxifying
Gelonghui, April 1 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that the therapeutic function of the pediatric clean-up and detoxification granules produced by the company is to clear heat and detoxify. It is used for external warmth, internal fever caused by internal heat, high fever, sore throat, heavy cough with phlegm, and dry stools.
Xinbang Pharmaceutical (002390.SZ): The company has subsidiaries that can provide molecular pathology diagnosis services
Gelonghui, April 1 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that the company has affiliated institutions that can provide molecular pathology diagnosis services.
Xinbang Pharmaceutical (002390.SZ) has spent 165 million yuan to buy back 1.92% of its shares
Xinbang Pharmaceutical (002390.SZ) issued an announcement. As of March 31, 2024, the company has repurchased a total of shares...
Xinbang Pharmaceutical (002390.SZ): It has developed 9 medicinal and food homologous foods, including Shanggong Tongde Huangjing tablets, Jingshan drink solid drinks, Huier high-solid drinks, and Mengxiang plant solid drinks
Gelonghui, March 27 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that in terms of health products, the company has developed 9 types of medicinal homologous food products, including Shanggong Tongde Huang tablets, Jingshan solid drinks, Huier high-solid drinks, and 5 types of health products such as Shanggong Jiaotai foot bath and traditional Chinese medicine sachets.
Xinbang Pharmaceutical (002390.SZ): Produced Yixin Shu capsules, Maixukang capsules, ginkgo biloba leaves, and dengzhanhuaditin for middle-aged and elderly people
Gelonghui, March 27 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that the company produced Yixinshu capsules, Maxukang capsules, ginkgo biloba leaves, and Dengzhan flower triplin are suitable for middle-aged and elderly people.
Earnings Growth of 1.1% Over 3 Years Hasn't Been Enough to Translate Into Positive Returns for Guizhou Xinbang Pharmaceutical (SZSE:002390) Shareholders
If you love investing in stocks you're bound to buy some losers. Long term Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390) shareholders know that all too well, since the share price is down co
Xinbang Pharmaceutical (002390.SZ): In the first half of 2023, sales expenses accounted for about 5% of revenue, and management expenses accounted for about 6% of revenue
Gelonghui, March 15 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that in the first half of 2023, sales expenses accounted for about 5% of revenue, and management expenses accounted for about 6% of revenue. The company effectively controlled various expenses through budget management. The sales expenses incurred in the first half of 2023 were 173.6613 million yuan, a decrease of about 10% over the same period of the previous year; management expenses were 206.643 million yuan, a decrease of about 8% over the same period last year. Currently, the company's various operations are smooth and orderly. The company's business involves the three major sectors of medical services, pharmaceutical distribution and pharmaceutical manufacturing, 20
Xinbang Pharmaceutical (002390.SZ): A total of 1.92% shares have been repurchased
Gelonghui, March 1, 丨 Xinbang Pharmaceutical (002390.SZ) announced that as of February 29, 2024, the cumulative number of shares repurchased by the company was 37,232,540 shares, accounting for 1.92% of the company's total share capital. The highest transaction price was 4.87 yuan/share, the lowest transaction price was 3.31 yuan/share, and the total transaction amount was 165 million yuan (excluding transaction fees).
Xinbang Pharmaceutical (002390.SZ): The recent wildfires in Guizhou Province had no impact on the company's Chinese herbal medicine planting base
Gelonghui Feb. 26丨An investor asked Xinbang Pharmaceutical (002390.SZ) on the investor interactive platform, “How much impact did the Guizhou wildfires have on the cultivation of Chinese herbal medicines in your company? Does your company have a Chinese herbal medicine planting base in the wildfire area?” The company replied that the recent wildfires in Guizhou Province had no impact on the company's Chinese herbal medicine planting base, and that the company and relevant partners will also actively take corresponding preventive measures.
Xinbang Pharmaceutical (002390.SZ): A total cost of about 148 million yuan to buy back 1.66% of the shares
Gelonghui, Feb. 1 | Xinbang Pharmaceutical (002390.SZ) announced that as of January 31, 2024, the cumulative number of shares repurchased by the company was 32,225,940 shares, accounting for 1.66% of the company's total share capital. The highest transaction price was 4.87 yuan/share, the minimum transaction price was 4.21 yuan/share, and the total transaction amount was about 148 million yuan (excluding transaction fees).
Is Guizhou Xinbang Pharmaceutical (SZSE:002390) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to rui
Xinbang Pharma Chairman Buys 14 Million Yuan More Shares
Guizhou Xinbang Pharmaceutical (SHE:002390) Chairman Ji An has increased her personal holdings in the company, citing her confidence in the company's future and development prospects. Anji purchased 3
Xinbang Pharmaceutical (002390.SZ): A total cost of 127 million yuan to buy back 1.42% of the shares
Gelonghui, January 3, 丨 Xinbang Pharmaceutical (002390.SZ) announced that as of December 31, 2023, the cumulative number of shares repurchased by the company was 27,531,540 shares, accounting for 1.42% of the company's total share capital. The highest transaction price was 4.87 yuan/share, the minimum transaction price was 4.42 yuan/share, and the total transaction amount was 127 million yuan (excluding transaction fees).
Xinbang Pharmaceutical (002390.SZ): Chairman An Ji increased its holdings by 3.1062 million shares
Gelonghui, January 2, 丨 Xinbang Pharmaceutical (002390.SZ) announced that on January 2, 2024, the company received a notice from Ms. An Ji, the chairman of the company. Based on her confidence in the company's future sustainable development prospects and recognition of the company's long-term investment value, Ms. Anji increased her shareholding by 3.1062 million shares through the Shenzhen Stock Exchange trading system through centralized bidding transactions on December 29, 2023.
Xinbang Pharmaceutical (002390.SZ): The company's inventory showed no signs of depreciation, and the short-term impact of Chinese herbal medicine price waves on the company's operations was minimal
Gelonghui, December 28 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that the company's Chinese herbal medicines are mainly used in the company's own production and operation, and their procurement and production have long-term plans and arrangements, and the relevant Chinese herbal medicine varieties will set a safe inventory according to the company's actual production needs. When the prices of some varieties of Chinese herbal medicines are relatively low, the company will make a certain amount of strategic reserves. Up to now, there are no signs of depreciation in the company's inventory, and the short-term impact of Chinese herbal medicine price waves on the company's operations is minimal. The company's investment funds mainly focus on medical services, medical informatization, high added value and high threshold
Xinbang Pharmaceutical (002390.SZ): The number of patients treated for upper respiratory infections in affiliated hospitals has increased recently
Gelonghui, December 5, Xinbang Pharmaceutical (002390.SZ) said on an interactive platform that due to seasonal factors, the number of patients treated for upper respiratory infections in the company's hospitals has recently increased.
Xinbang Pharmaceutical (002390.SZ): Repurchased 1.10% of shares at a total cost of 999.789 million yuan
Gelonghui (002390.SZ) announced on December 1 | Xinbang Pharmaceutical (002390.SZ) announced that as of November 30, 2023, the company's cumulative number of shares repurchased was 21.461.54 million shares, accounting for 1.10% of the company's total share capital. The highest transaction price was 4.87 yuan/share, the lowest transaction price was 4.54 yuan/share, and the total transaction amount was 999.789.27 million yuan (excluding transaction fees).
While Shareholders of Guizhou Xinbang Pharmaceutical (SZSE:002390) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown
Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390) shareholders should be happy to see the share price up 11% in the last quarter. But that doesn't help the fact that the three year return is l
No Data